Appointment of Additional Director (Woman Director)
Pfizer Ltd has informed BSE that the Board of Directors of the Company has appointed Dr. Anurita Majumdar as an Additional Director (Woman Director) of the Company, designated as Executive Director, Medical with effect from November 04, 2016 for a period of 5 years. The appointment of Dr. Anurita Majumdar will be subject to the approval of shareholders at the ensuing Annual General Meeting of the Company. Updates
Pfizer Ltd has informed BSE that a teleconference call has been scheduled with the analysts on November 07, 2016, at 4.30 p.m. to discuss the Companys financial performance for the second quarter and half year ended September 30, 2016. Resignation of Non-executive (Woman) Director
Pfizer Ltd has informed BSE that Ms. Lu Hong has resigned as the Non-executive (Woman) Director from the Board of the Company effective November 04, 2016, on account of her relocation to USA for taking up a global role with Pfizer Inc., USA. Results Press Release for September 30, 2016
Pfizer Ltd has informed BSE about : 1. Result Press Release for the period ended September 30, 2016 Announces Q2 results (Standalone) & Limited Review Report (Standalone) for the Quarter ended September 30, 2016
Pfizer Ltd has announced the following Unaudited Standalone results for the quarter ended September 30, 2016:The Company has posted a net profit of Rs. 1263.30 million for the quarter ended September 30, 2016 as compared to Rs. 828.40 million for the quarter ended September 30, 2015. Total Income has increased from Rs. 5472.00 million for the quarter ended September 30, 2015 to Rs. 5819.60 million for the quarter ended September 30, 2016. Pfizer profit just misses estimates; company scraps cholesterol drug
The drugmaker earned 61 cents per share in the third quarter, excluding special items, missing the average analyst estimate by 1 cent Q2 results on Nov 04, 2016
Pfizer Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on November 4, 2016, inter alia, to consider and take on record the unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2016 (Q2).Further, the Trading Window for trading in the Equity shares of the Company will be closed from October 26, 2016 to November 6, 2016, both days inclusive. Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Pfizer Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended September 30, 2016
Pfizer Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here Novartis challenges Pfizer with strong breast cancer drug data
Novartis' ribociclib to take on Pfizer blockbuster Ibrance